Abstract: The present application provides compositions and methods for determining a disease or condition in a subject. The method comprises contacting a body fluid with a molecule comprising a reporter thereof and the reported is cleaved by an agent in the body fluid. Diseases and conditions that can be determined by the method are also described.

Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.

Abstract: The present disclosure provides a method of preparing a high density culture of bacteria. The method provides a bioreactor comprising a fermentation tank, a perfusion system, a medium, and a cell separator; preparing an inoculum comprising a bacteria consortia with at least two bacteria species; inoculating the fermentation tank with the inoculum to form a fermentation culture; and growing the bacteria consortia until it has reached a target density of at least about 1012 CFU/mL.

Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):

Abstract: Arrangements of the innovation relate to a micro-coring system configured to harvest a plurality of cores, either sequentially or simultaneously. In one arrangement, the micro-coring system comprises a harvesting tool configured to harvest and transfer at least one tissue core from a donor site to a recipient site, the at least one tissue core having a diameter of between about 1.0 mm and 3.0 mm diameter. In one arrangement, the harvesting tool comprises: a coring tool configured to penetrate tissue at the donor site and capture a tissue core from the tissue, and an extractor pin disposed within an aperture extending along a longitudinal axis of the coring tool, the extractor pin configured to extract the core from the coring tool.

Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Abstract: The present invention relates to methods for treating a subject with risk factors for progression to iRORA, iRORA, nGA, cRORA, GA, AMD, intermediate AMD, dry AMD, and/or wet AMD, in a subject in need thereof comprising administration of an effective amount of an anti-C 5 agent or a pharmaceutically acceptable salt thereof. The present invention also relates to methods for treating an ophthalmological disease, disorder, and/or condition in a subject with high-risk drusen, comprising administration of an effective amount of an anti-C 5 agent or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a nitrogen-containing heterocyclic compound, a method for preparing the same and a use of the same. The present disclosure provides a nitrogen-containing heterocyclic compound of formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof, and the nitrogen-containing heterocyclic compound is expected to treat and/or prevent various RAS-related diseases.

Abstract: The present invention enables simultaneous and stable expression of a plurality of foreign genes by using a stealthy RNA gene expression system that is a complex that does not activate the innate immune mechanism and is formed from an RNA-dependent RNA polymerase, a single-strand RNA binding protein, and negative-sense single-strand RNAs including the following (1) to (8): (1) a target RNA sequence that codes for any protein or functional RNA; (2) an RNA sequence forming a noncoding region and derived from mRNA expressed in animal cells; (3) a transcription initiation signal sequence recognized by the RNA-dependent RNA polymerase; (4) a transcription termination signal sequence recognized by the polymerase; (5) an RNA sequence containing a replication origin recognized by the polymerase; (6) an RNA sequence that codes for the polymerase and of which codons are optimized for the species from which an introduction target cell is derived; (7) an RNA sequence that codes for a protein for regulating the activity o

Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

Abstract: The present invention provides methods and compositions for improving efficacy of viral transduction of cells. More particularly, the present invention provides methods and materials useful for safely and reliably improving the efficiency of methods and materials useful for safely and reliably improving the efficiency of methods for transducing cells, such as human hematopoietic stem cells (HSC), with viruses and/or viral vectors. The compositions and methods are useful for therapeutic indications amenable to treatment with hematopoietic stem cell gene therapies.

Abstract: Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: administering a prophylactically effective amount of an anti-CD3 antibody to a non-diabetic subject who is at risk of T1D, wherein the prophylactically effective amount has a cumulative dose of about 10,500 ?g/m2 to about 14,000 ?g/m2.

Abstract: Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.

Abstract: The present disclosure provides antimicrobial coating compositions that are used to form residual antimicrobial coatings on medical implements and medical devices including the components of medical equipment such as CPAP/BiPAP machines. Antimicrobial coating compositions comprise at least one of an organosilane (R1O)3Si—R2—Z, an organic amine R9R10R11N, a titanium (IV) species, a 1,2-diol, an ?-hydroxy acid, a ?-hydroxy acid, and an organosilane grafted parylene polymer, wherein R1 is H, alkyl, substituted alkyl, aryl or substituted aryl, R2 is a bivalent linker, Z is a nucleophile, leaving group, or quaternary nitrogen substituent, and R9, R10, and R11 are independently H, alkyl, substituted alkyl, aryl, substituted aryl or cyclic.

Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

Abstract: Methods and systems for extracellular vesicle characterization are provided herein. Embodiments of the methods include inputting measured physical, biological, or chemical aspects of extracted extracellular vesicles. Next, an information architecture that characterizes relationships between biological entities and diseases in humans or other vertebrates is generated. Then, relationships between the measured physical, biological, or chemical aspects of the isolated extracellular vesicles with the information architecture are automatically inferred, thereby characterizing extracellular vesicles.

Abstract: The present disclosure provides methods of assessing tumor progression in a subject. In an aspect, a method for assessing tumor progression of a subject can comprise: measuring a count of a plurality of cell-free DNA (cfDNA) molecules at each of a plurality of genomic regions, wherein the plurality of cfDNA molecules is obtained or derived from a bodily fluid sample of the subject; processing the counts measured at each of the genomic regions to obtain quantitative measures of deviation of the counts relative to a plurality of reference values, to produce deviation scores; determining a difference between the deviation scores and a plurality of reference deviation scores to produce changes in deviation (CID) values, and calculating a CID score based on the CID values; and detecting a tumor progression of the subject when the CID score satisfies a pre-determined criterion.

Abstract: The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.

Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures.